Latest revenue
$75.4M
as of 2026-03-31
Latest net income
$2.6M
as of 2026-03-31
Net margin
3.4%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $370.0M
- Enterprise value
- $370.0M
- P/E (trailing)
- 24.8×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $10.18
- 52-wk low
- $5.93
- Beta
- —
- Shares out
- 38.3M
5-year trend
What this company does
Item 1. Business Company Overview Viemed Healthcare, Inc. (the "Company" or "Viemed"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women’s health products and services. The Company’s primary service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Viemed’s primary objective is to drive growth by increasing the number of patients served and the level of care provided through its technology-enabled, home-based clinical care and chronic…
AI summary unavailable — showing raw filing excerpt
Generated from VMD's filing dated 2026-03-04
Key risks
Item 1A. Risk Factors Risks Related to Our Industry and Business We compete against companies that have longer operating histories and greater resources, which may result in reduced profit margins and loss of market share. The respiratory care industry is highly competitive and dynamic and may become more competitive as new players enter the market. Certain competitors will be subsidiaries or divisions of larger, much better capitalized companies. Certain competitors will have vertically integrated manufacturing and services sectors of the market. We may have less capital and may encounter greater operational challenges in serving the market. Better capitalized competitors may also be able…
AI summary unavailable — showing raw filing excerpt
Generated from VMD's filing dated 2026-03-04
Profitability
Gross margin
57.5%
3.2%Operating margin
8.5%
6.4%Net margin
5.5%
10.0%Return on equity
10.6%
23.1%Return on assets
7.5%
17.9%Leverage
Debt / equity
0.41×
17.1%Long-term debt / equity
0.08×
192.0%Debt / assets
28.9%
12.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $75.4M | +27.5% | $2.6M | -1.6% | 3.4% |
Q4 2025 2025-12-31 | $76.2M | +25.5% | $5.6M | +30.7% | 7.4% |
Q3 2025 2025-09-30 | $71.9M | +24.0% | $3.5M | -9.4% | 4.9% |
Q2 2025 2025-06-30 | $63.1M | +14.7% | $3.2M | +115.1% | 5.0% |
Q1 2025 2025-03-31 | $59.1M | +16.9% | $2.6M | +63.8% | 4.4% |
Q4 2024 2024-12-31 | $60.7M | — | $4.3M | — | 7.1% |
Q3 2024 2024-09-30 | $58.0M | +17.4% | $3.9M | +32.9% | 6.7% |
Q2 2024 2024-06-30 | $55.0M | +26.9% | $1.5M | -37.0% | 2.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Misc Health & Allied Services, NEC · SIC 8090
Your notes
Keep private notes on VMD — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$3.2M
Net activity
−$3.2M
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2026-03-20 | Michael Moore President | Sale | 65,000 | $8.77 | $570.0K | |
| 2026-03-19 | Michael Moore President | Sale | 40,232 | $9.21 | $370.5K | |
| 2026-03-18 | Michael Moore President | Sale | 31,570 | $9.42 | $297.4K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns VMD
Institutional value
$98.0M
Total shares held
11.1M
Distinct holders
82
-48 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 4.6M | $42.6M | -3.5K (-0.1%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $12.0M | — | New |
| 3 | First Eagle Investment Management, LLC | 529.7K | $4.9M | +11.5K (+2.2%) | Added |
| 4 | TOCQUEVILLE ASSET MANAGEMENT L.P. | 472.1K | $4.3M | +0 (+0.0%) | No change |
| 5 | BARD ASSOCIATES INC | 339.9K | $3.1M | +597 (+0.2%) | Added |
| 6 | Penbrook Management LLC | 272.4K | $2.5M | +850 (+0.3%) | Added |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 243.0K | $2.2M | — | New |
| 8 | VANGUARD FIDUCIARY TRUST CO | 234.3K | $2.2M | — | New |
| 9 | Creative Planning | 220.4K | $2.0M | — | New |
| 10 | UBS Group AG | 217.8K | $2.0M | +131.6K (+152.7%) | Added |
| 11 | Hillsdale Investment Management Inc. | 199.1K | $1.8M | — | New |
| 12 | DIMENSIONAL FUND ADVISORS LP | 189.9K | $1.7M | -3.9K (-2.0%) | Trimmed |
| 13 | JANE STREET GROUP, LLC | 151.5K | $1.4M | +47.6K (+45.8%) | Added |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 142.6K | $1.3M | +21.4K (+17.7%) | Added |
| 15 | JPMORGAN CHASE & CO | 114.3K | $1.1M | -40.5K (-26.2%) | Trimmed |
| 16 | SummerHaven Investment Management, LLC | 110.5K | $1.0M | -11.5K (-9.4%) | Trimmed |
| 17 | FIRST TRUST ADVISORS LP | 105.2K | $968.8K | +608 (+0.6%) | Added |
| 18 | North Star Investment Management Corp. | 100.0K | $921.0K | — | New |
| 19 | Nuveen, LLC | 94.4K | $869.7K | -5.1K (-5.1%) | Trimmed |
| 20 | SALEM INVESTMENT COUNSELORS INC | 87.0K | $801.4K | +23.9K (+37.9%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once VMD's latest filing finishes processing.